Traws Pharma, Inc. Key Metrics

2 years of history · ending 2025-12-31 · SEC EDGAR

Forensics

Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.

F-Score (Piotroski 0-9)

Z-Score (Altman; <1.81 = distress)

Per Share Metrics

Expense Ratios

Working Capital Analysis

Earnings Forecasts

Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).

Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.

EPS — Consensus vs Actual

Beat / Miss vs Estimate

Stock Price on Earnings Dates

Traws Pharma, Inc. — Effective Tax Rate ReconciliationNEW

Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.

Effective Rate Trend

Reconciliation LineFY2020FY2021FY2022FY2023FY2024FY2025
Federal Statutory Rate21.00%21.00%21.00%21.00%21.00%21.00%
State & Local Income Taxes7.80%8.00%1.30%5.40%0.50%
Foreign Rate Differential0.10%
Other Adjustments-0.10%-0.10%-1.00%-4.10%-1.60%
Nondeductible Expenses-0.20%0.40%-0.10%-17.90%
Valuation Allowance Change-29.10%-34.10%19.60%-21.90%83.60%
Effective Tax Rate-0.10%0.00%0.00%0.00%0.00%

Cash vs Accrual

ItemFY2020FY2021FY2022FY2023FY2024FY2025
Income Tax Expense (Accrual)$4.0K
Income Taxes Paid (Cash)